Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia
| Autor: | Ruth LaPushin, Mary L. Browning, Alessandra Ferrajoli, Susan O'Brien, William G. Wierda, Michael J. Keating, Stefan Faderl |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
medicine.medical_specialty CD52 Antibodies Neoplasm Continuous infusion Chronic lymphocytic leukemia Salvage therapy Antineoplastic Agents Pilot Projects Antibodies Monoclonal Humanized Gastroenterology Internal medicine medicine Humans In patient Infusions Intravenous Alemtuzumab Vidarabine Aged Salvage Therapy business.industry Antibodies Monoclonal Hematology General Medicine Middle Aged medicine.disease Leukemia Lymphocytic Chronic B-Cell Tolerability Drug Resistance Neoplasm Immunology Female business medicine.drug |
| Zdroj: | European Journal of Haematology. 80:296-298 |
| ISSN: | 1600-0609 0902-4441 |
| DOI: | 10.1111/j.1600-0609.2007.01023.x |
| Popis: | We evaluated the activity and tolerability of alemtuzumab given as a continuous infusion for 7 d followed by subcutaneous administration for 11 wk as salvage therapy for 10 patients with fludarabine-refractory chronic lymphocytic leukemia. The continuous infusion of alemtuzumab was well tolerated. The typical infusion reaction seen with intravenous alemtuzumab was abolished. Two patients achieved a partial response with an overall response rate of 20%. Alemtuzumab levels were measured in four patients and detectable levels were obtained in three. Clinical activity needs to be confirmed in a larger patient population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|